PriceTargets.com logo

Medicenna Therapeutics - MDNA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$1.50 As of 11/20/2024 01:00 AM ET
▼ -0.12 (-7.41%)

This chart shows the closing price for MDNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medicenna Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDNA

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Medicenna Therapeutics in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$1.50.

This chart shows the closing price for MDNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Medicenna Therapeutics. This rating has held steady since November 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/29/2022GuggenheimReiterated RatingBuyC$2.00
9/29/2022HC WainwrightLower TargetBuyC$4.00
8/16/2022JonestradingLower TargetC$6.00 ➝ C$5.00
8/16/2022Bloom BurtonLower TargetBuyC$9.00
8/10/2022OppenheimerReiterated RatingBuyC$8.00
7/28/2022Bloom BurtonReiterated RatingBuyC$11.00
6/23/2022HC WainwrightReiterated RatingBuyC$5.00
6/22/2022Maxim GroupInitiated CoverageBuyC$4.00
5/3/2022Maxim GroupInitiated CoverageBuyC$4.00
4/13/2022Brookline Capital AcquisitionBoost TargetBuyC$14.00
2/10/2022Maxim GroupInitiated CoverageBuyC$7.00
2/10/2022HC WainwrightReiterated RatingBuyC$7.00
11/15/2021HC WainwrightReiterated RatingBuyC$7.00
9/22/2021Bloom BurtonInitiated CoverageBuyC$11.00
9/14/2021Maxim GroupReiterated RatingBuyC$9.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Medicenna Therapeutics logo
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Read More

Today's Range

Now: C$1.50
Low: C$1.48
High: C$1.64

50 Day Range

MA: C$2.10
Low: C$1.45
High: C$2.51

52 Week Range

Now: C$1.50
Low: C$0.38
High: C$2.98

Volume

38,304 shs

Average Volume

107,149 shs

Market Capitalization

C$114.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicenna Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Medicenna Therapeutics in the last year:
View the latest analyst ratings for MDNA.

What is the current price target for Medicenna Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Medicenna Therapeutics in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Medicenna Therapeutics in the next year.
View the latest price targets for MDNA.

What is the current consensus analyst rating for Medicenna Therapeutics?

Medicenna Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDNA.

What other companies compete with Medicenna Therapeutics?

Other companies that are similar to Medicenna Therapeutics include VBI Vaccines, Chemtrade Electrochem Inc,, Aimia, Fennec Pharmaceuticals and Andean Precious Metals. Learn More about companies similar to Medicenna Therapeutics.

How do I contact Medicenna Therapeutics' investor relations team?

Medicenna Therapeutics' physical mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The company's listed phone number is +1-403-6807898. The official website for Medicenna Therapeutics is www.medicenna.com. Learn More about contacing Medicenna Therapeutics investor relations.